MRI as primary endpoint of clinical trials should MRI be the PEP of phase III trials in MS? YES

被引：0
|
作者：
Sormani, M. P. [1 ]
机构：
[1] Univ Genoa, Genoa, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
106
引用
收藏
页码：28 / 28
页数：1
相关论文
共 50 条
  • [1] Should MRI be the primary endpoint of phase III trials in MS? No
    Weinshenker, B. G.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 28 - 28
  • [2] MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: Yes
    Sormani, Maria Pia
    De Stefano, Nicola
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (03) : 280 - 281
  • [3] Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis?
    Rossman, Ian T.
    Cohen, Jeffrey A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (05) : 489 - 491
  • [4] MRI measures should be a primary outcome endpoint in phase III randomized controlled trials in multiple sclerosis: No
    Ebers, George C.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (03) : 282 - 283
  • [5] MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary
    Hutchinson, Michael
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (03) : 284 - 285
  • [6] MRI monitoring of MS in clinical trials
    Miller, DH
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2002, 104 (03) : 236 - 243
  • [7] MRI findings in blinded trials should be available to treating physicians - Yes
    Vukusic, Sandra
    Lebrun-Frenay, Christine
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (06) : 812 - 813
  • [8] Advanced MRI measures like DTI or fMRI should be outcome measures in future clinical trials - YES
    Kapoor, Raj
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (11) : 1454 - 1455
  • [9] Success in Meeting the Primary Endpoint in Phase III Trials: A Comparison of Industry and Cooperative Group Trials
    Djulbegovic, Benjamin
    Kumar, Ambuj
    Miladinovic, Branko
    Mhaskar, Asmita
    Reljic, Tea
    Galeb, Sanja
    Mhaskar, Rahul
    Iztok, Hozo
    Tu, Dongsheng
    Stanton, Heather
    Booth, Christopher M.
    Meyer, Ralph M.
    BLOOD, 2011, 118 (21) : 237 - 237
  • [10] HOW SHOULD THE PRIMARY ENDPOINT BE ANALYSED IN RHEUMATOID ARTHRITIS TRIALS WHICH MANDATE RESCUE PRIOR TO THE CLINICAL ENDPOINT? ANALYSIS OF THREE PHASE 3 TRIALS OF TOFACITINIB
    Fleischmann, R.
    Gruben, D.
    Krishnaswami, S.
    Zwillich, S. H.
    Benda, B.
    Mebus, C. A.
    Bradley, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 207 - 207
12345